Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro

Psychopharmacology

Volumn 231, Issue 14, 2014, Pages 2771-2783

  Janowsky, Aaron ^a,b   Eshleman, Amy J ^a,b   Johnson, Robert A ^a,b   Wolfrum, Katherine M ^b   Hinrichs, David J ^a,c   Yang, Jongtae ^d   Zabriskie, T Mark ^d   Smilkstein, Martin J ^a,e   Riscoe, Michael K ^a,d,e  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e PORTLAND STATE UNIVERSITY   (United States)

Author keywords

Chloroquine; Dopamine receptor; LSD; Malaria; Mefloquine; Neurotransmitter; Psychotomimetic; Quinine; Serotonin receptor; Transporter

Indexed keywords

CHLOROQUINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; INOSITOL PHOSPHATE; MEFLOQUINE; N,N DIMETHYLTRYPTAMINE; NEUROTRANSMITTER RECEPTOR; NORADRENALIN TRANSPORTER; PSYCHEDELIC AGENT; RADIOLIGAND; SEROTONIN; SEROTONIN 2A RECEPTOR; ANTIMALARIAL AGENT; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; NEUROTRANSMITTER UPTAKE; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR AFFINITY; SEROTONINERGIC SYSTEM; STEREOCHEMISTRY; SYNAPTIC TRANSMISSION; ANIMAL; CHEMISTRY; CHO CELL LINE; COMPARATIVE STUDY; CRICETULUS; DRUG EFFECTS; HAMSTER; HEK293 CELL LINE; METABOLISM; MOUSE; STEREOISOMERISM;

ANIMALS; ANTIMALARIALS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHLOROQUINE; CHO CELLS; CRICETINAE; CRICETULUS; HALLUCINOGENS; HEK293 CELLS; HUMANS; MEFLOQUINE; MICE; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM;

EID: 84903598603     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3446-0     Document Type: Article

References (50)

1. AlKadi HO (2007) Antimalarial drug toxicity: a review. Chemotherapy 53:385-391
2. Amabeoku GJ, Farmer CC (2005) Gamma-aminobutyric acid and mefloquine-induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatr 29(6):917-921
3. Caridha D, Yourick D, Cabezas M, Wolf L, Hudson TH, Dow GS (2008) Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin. Antimicrob Agents Chemother 52(2):684-693
4. Carroll FI, Blackwell JT (1974) Optical isomers of aryl-2- piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry. J Med Chem 17(2):210-219
5. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
6. Combrinck JM, Mabotha TE, Ncokazi KK, Ambele MA, Taylor D, Smith PJ, Hoppe HC, Egan TJ (2013) Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem Biol 8(1):133-137
7. Cruikshank SJ, Hopperstad M, Younger M, Connors BW, Spray DC, Srinivas M (2004) Potent block of Cx36 and Cx50 gap junction channels by mefloquine. Proc Natl Acad Sci U S A 101(33):12364-12369
8. Dow GS, Milner E, Bathurst I, Bhonsle J, Caridha D, Gardner S, Gerena L, Kozar M, Lanteri C, Mannila A, McCalmont W, Moon J, Read KD, Norval S, Roncal N, Shackleford DM, Sousa J, Steuten J, White KL, Zeng Q, Charman SA (2011) Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. Malar J 10:150
9. Dzierszinski F, Coppin A, Mortuaire M, Dewailly E, Slomianny C, Ameisen JC, DeBels F, Tomavo S (2002) Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro. Antimicrob Agents Chemother 46(10):3197-3207
10. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K (2000) Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT2A and 5-HT2C receptors. Synapse 35:144-150
11. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A (1999) Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289(2):877-885
12. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85(12):1803-1815
13. Gatch MB, Forster MJ, Janowsky A, Eshleman AJ (2011) Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther 338(1):280-289
14. Gazi L, Bobirnac I, Danzeisen M, Schüpbach E, Langenegger D, Sommer B, Hoyer D, Tricklebank M, Schoeffter P (1999) Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells. Br J Pharmacol 128(3):613-620
15. Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS (2008) Antagonists of the human adenosine A2A receptor: Part 1. Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett 18(9):2916-2919
16. Glimcher PW (2011) Understanding dopamine and reinforcement learning: the dopamine reward prediction error hypothesis. Proc Natl Acad Sci U S A 108(Suppl 3):15647-15654
17. Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61:364-381
18. Haynes RK, Cheu KW, Chan HW, Wong HN, Li KY, Tang MM, Chen MJ, Guo ZF, Guo ZH, Sinniah K, Witte AB, Coghi P, Monti D (2012) Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model - a unifying proposal for drug action. Chem Med Chem 7(12):2204-2226
19. Hood JE, Jenkins JW, Milatovic D, Rongzhu L, Aschner M (2010) Mefloquine induces oxidative stress and neurodegeneration in primary rat cortical neurons. Neurotoxicology 31(5):518-523
20. Iglesias R, Locovei S, Roque A, Alberto AP, Dahl G, Spray DC, Scemes E. (2008) P2X7 receptor-Pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol 295:C752-60
21. Jones R, Kunsman G, Levine B, Smith M, Stahl C (1994) Mefloquine distribution in postmortem cases. Forensic Sci Int 68(1):29-32
22. Kanagarajadurai K, Malini M, Bhattacharya A, Panicker MM, Sowdhamini R (2009) Molecular modeling and docking studies of human 5-hydroxytryptamine 2A (5-HT2A) receptor for the identification of hotspots for ligand binding. Mol Biosyst 5(12):1877-1888
23. Kelly JX, Smilkstein MJ, Brun R, Wittlin S, Cooper RA, Lane KD, Janowsky A, Johnson RA, Dodean RA, Winter R, Hinrichs DJ, Riscoe MK (2009) Discovery of dual function acridones as a new antimalarial chemotype. Nature 459(7244):270-273
24. Kennedy K (2009) Army scales back use of anti-malaria drug. Army Times, March 24:2009
25. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, Bickerdike M (2004) Pharmacological characterisation of the agonist radioligand binding site of 5HT(2A), 5HT(2B) and 5HT(2C) receptors. Naunyn-Schmeideberg's Arch Pharmacol 370:114-123
26. MacLean D.S. (2013) Crazy Pills. The New York Times. August 7. Available at http://www.nytimes.com/2013/08/08/opinion/crazy-pills.html?-r=0
27. Marona-Lewicka D, Nichols CD, Nichols DE (2011) An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology 61(3):503-512
28. Milatovic D, Jenkins JW, Hood JE, Yu Y, Rongzhu L, Aschner M (2011) Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase. Neurotoxicology 32:578-585
29. Minuzzi L, Cumming P (2010) Agonist binding fraction of dopamine D2/3 receptors in rat brain: a quantitative autoradiographic study. Neurochem Int 56(6-7):747-752
30. Miyake N, Miyamoto S, Jarskog LF (2012) New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress? Clin Schizophr Relat Psychoses 6(3):122-133
31. Neve KA, Neve RL (1997) Molecular biology of dopamine receptors. In: Neve KA, Neve RL (eds) The dopamine receptors. Humana Press, Totowa
32. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181
33. Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. (2002) Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N- diethyllysergamide (LSD). J Med Chem 45(19):4344-4349
34. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 14:295-314
35. Pham YT, Nosten F, Farinotti R, White NJ, Gimenez F (1999) Cerebral uptake of mefloquine enantiomers in fatal cerebral malaria. Int J Clin Pharmacol Ther 37(1):58-61
36. Rabin RA, Regina M, Doat M, Winter JC (2002) 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72(1-2):29-37
37. Sarihi A, Mirnajafi-Zadeh J, Jiang B, Sohya K, Safari MS, Arami MK, Yanagawa Y, Tsumoto T (2012) Cell type-specific, presynaptic LTP of inhibitory synapses on fast-spiking GABAergic neurons in the mouse visual cortex. J Neurosci 32(28):13189-13199
38. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG. (2011) Use of mefloquine in children- a review of dosage, pharmacokinetics and tolerability data. Malar J 10:292-302
39. Schlagenhauf P, Johnson R, Schwartz E, Nothdurft HD, Steffen R (2009) Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study. J Travel Med 16(1):42-45
40. Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, White NJ (1999) Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther 66(5):472-484
41. Sleight AJ, Stam NJ, Mutel V, Vanderheyden PM (1996) Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. Biochem Pharmacol 51(1):71-76
42. C receptors. Br J Pharmacol 153(8):1686-1696
43. Thompson AJ, Lochner M, Lummis SC (2007) The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors. Br J Pharmacol 151(5):666-677
44. Thomson AM, West DC, Lodge D (1985) An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature 313(6002):479-481
45. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178:440-466
46. Toovey S (2009) Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 7(1):2-6
47. Van Riemsdijk MM, Sturkenboom MC, Pepplinkhuizen L, Stricker BH (2005) Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J Clin Psychiatry 66(2):199-204
48. Wang Y, Denisova JV, Kang KS, Fontes JD, Zhu BT, Belousov AB. (2010) Neuronal gap junctions are required for NMDA receptor-mediated excitotoxicity: implications in ischemic stroke. J Neurophysiol 104(6):3551-3556.
49. Weidekamm E, Rüsing G, Caplain H, Sörgel F, Crevoisier C (1998) Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 54(8):615-619
50. Weiss SM, Benwell K, Cliffe IA, Gillespie RJ, Knight AR, Lerpiniere J, Misra A, Pratt RM, Revell D, Upton R, Dourish CT (2003) Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. Neurology 61(11 Suppl 6):S101-S106